Larimar Therapeutics Statistics
Total Valuation
LRMR has a market cap or net worth of $169.09 million. The enterprise value is -$29.26 million.
Important Dates
The next estimated earnings date is Monday, March 17, 2025, after market close.
| Earnings Date | Mar 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LRMR has 63.81 million shares outstanding. The number of shares has increased by 28.05% in one year.
| Current Share Class | 63.81M |
| Shares Outstanding | 63.81M |
| Shares Change (YoY) | +28.05% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 50.05% |
| Float | 31.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.10, with a Debt / Equity ratio of 0.03.
| Current Ratio | 13.10 |
| Quick Ratio | 12.57 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.50% and return on invested capital (ROIC) is -30.54%.
| Return on Equity (ROE) | -44.50% |
| Return on Assets (ROA) | -28.55% |
| Return on Invested Capital (ROIC) | -30.54% |
| Return on Capital Employed (ROCE) | -36.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.54M |
| Employee Count | 42 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.02% in the last 52 weeks. The beta is 0.77, so LRMR's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -74.02% |
| 50-Day Moving Average | 3.42 |
| 200-Day Moving Average | 6.54 |
| Relative Strength Index (RSI) | 35.53 |
| Average Volume (20 Days) | 504,849 |
Short Selling Information
The latest short interest is 5.38 million, so 8.42% of the outstanding shares have been sold short.
| Short Interest | 5.38M |
| Short Previous Month | 5.07M |
| Short % of Shares Out | 8.42% |
| Short % of Float | 17.27% |
| Short Ratio (days to cover) | 9.31 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -73.76M |
| Pretax Income | -58.34M |
| Net Income | -64.77M |
| EBITDA | -73.44M |
| EBIT | -73.76M |
| Earnings Per Share (EPS) | -$1.15 |
Full Income StatementBalance Sheet
The company has $203.71 million in cash and $5.36 million in debt, giving a net cash position of $198.35 million or $3.11 per share.
| Cash & Cash Equivalents | 203.71M |
| Total Debt | 5.36M |
| Net Cash | 198.35M |
| Net Cash Per Share | $3.11 |
| Equity (Book Value) | 198.40M |
| Book Value Per Share | 3.11 |
| Working Capital | 196.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$58.29 million and capital expenditures -$500,000, giving a free cash flow of -$58.79 million.
| Operating Cash Flow | -58.29M |
| Capital Expenditures | -500,000 |
| Free Cash Flow | -58.79M |
| FCF Per Share | -$0.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |